FDA Finalizes New Mandatory Opioid Addiction Risk Label Warnings
New mandatory warning labels will be required for all opioid painkillers, as part of a continuing effort by federal drug regulators to curb misuse and abuse of the powerful and addictive narcotic painkillers.
The U.S. Food and Drug Administration (FDA) issued a press release on December 15, announcing the final approval of new prescription opioid drug labeling requirements. The agency indicates the new warnings will not only to help protect patients and prevent more overdoses and abuse, but also encourage healthcare providers to take a “patient-centered” approach to prescribing opioid painkillers.
The new label requirements were proposed in April 2023, in response to the nation’s opioid crisis, with nearly 70% of all fatal drug overdoses in the U.S. involving opioid painkillers.
“While the FDA understands the importance of ensuring patients continue to have access to opioid analgesics in their pain management regimens, we believe it is equally important to ensure that patients and prescribers are fully aware of all the benefits and risks of treatment with opioid pain medicines,” Dr. Patrizia Cavazzoni, M.D., director of the Center for Drug Evaluation and Research, said in the press release. “Approving these class-wide labeling updates facilitates safer use of these medicines and furthers our goal to reduce the risks of nonmedical use and overdose.”
New Opioid Label Warning Requirements
The new label requirements call for drug makers to add the following new warnings to all opioid drug labels and prescription guides:
- The risk of overdose increases as the dosage increases for all pain medicines.
- Immediate-release opioids should not be used for an extended period of time unless a patient’s pain remains severe enough to require them and alternative treatment options continue to be inadequate.
- Many acute pain conditions treated in the outpatient setting require no more than a few days of opioid pain medicine.
- It is recommended to reserve extended-release and long-acting opioid pain medicines for severe and persistent pain that requires an extended treatment period with a daily opioid pain medicine and for which alternative treatment options are inadequate.
The new label requirement also includes a new warning about opioid-induced hyperalgesia, a potential side effect of opioid use that leads to an increase in pain or increased sensitivity to pain.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
The warning labels will also provide information on determining which symptoms are a part of opioid-induced hyperalgesia and which symptoms result from opioid tolerance and withdrawal, a serious concern among patients who begin to abuse prescription painkillers.
Opioid Abuse Crisis
The FDA said the new labeling requirements, much like the requirements for opioids to carry naloxone overdose reversal drug information, is a part of their effort to help protect the general public.
Opioids now account for nearly half of all fatal child poisonings in the U.S. Comparatively, in 2005, opioids accounted for roughly 24% of all child poisonings in the country.
The opioid crisis has been linked to the promotions of the drug manufacturers and the prescribing habits of doctors, who give patients prescriptions for narcotic painkillers, like Percocet and Tramadol, without a pain diagnosis in more than 30% of cases. Doctors have been repeatedly advised to prescribe the least opioid painkillers necessary.
Other research warns opioids, originally designed to treat cancer pain, should be avoided for treating back pain in older adults, and yet other studies have found that nearly one-quarter of adults with chronic pain used opioids for a minimum of three months, including adults suffering from back pain.
Get more articles like this sent directly to your inbox.
"*" indicates required fields
More Top Stories
A federal judge has scheduled the initial status conference for coordinated GLP-1 RA drug stomach paralysis lawsuit pretrial proceedings for March 14.
U.S. government attorneys now say they want each plaintiff in a Camp Lejeune lawsuit to prove specific causation, which seems to run counter to the intent of the law passed by Congress.
Those seeking to apply for leadership positions in Suboxone injury lawsuits have until March 1 to file with the court.